BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He FL, Wang L, Zhao HW, Fan ZH, Zhao MF, Dai S, Yue ZD, Liu FQ. Transjugular intrahepatic portosystemic shunt for severe jaundice in patients with acute Budd-Chiari syndrome. World J Gastroenterol 2015; 21(8): 2413-2418 [PMID: 25741149 DOI: 10.3748/wjg.v21.i8.2413] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Qiu B, Zhao MF, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Dai S, Yao JN, Liu FQ. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. World J Gastroenterol 2015; 21(43): 12439-12447 [PMID: 26604651 DOI: 10.3748/wjg.v21.i43.12439] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
2 He F, Zhao H, Dai S, Wu Y, Wang L, Huang H, Yue Z, Fan Z, Dong X, Liu F. Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome with diffuse occlusion of hepatic veins. Sci Rep. 2016;6:36380. [PMID: 27805025 DOI: 10.1038/srep36380] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
3 Patidar Y, Pal CK, Mukund A, Kumar G, Sarin SK. Retrospective comparative study of efficacy, safety and outcome of percutaneous intervention for Budd-Chiari syndrome patients with bilirubin less than 3 and 3-6 mg/dl. Br J Radiol 2021;94:20201157. [PMID: 33595338 DOI: 10.1259/bjr.20201157] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Knight GM, Clark J, Boike JR, Maddur H, Ganger DR, Talwar A, Riaz A, Desai K, Mouli S, Hohlastos E, Garcia Pagan JC, Gabr A, Stein B, Lewandowski R, Thornburg B, Salem R. TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy. Hepatology 2021;74:2735-44. [PMID: 34021505 DOI: 10.1002/hep.31915] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
5 Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr 2017;129:135-58. [PMID: 29063233 DOI: 10.1007/s00508-017-1262-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 12.4] [Reference Citation Analysis]
6 Mancuso A. Timing of treatment and outcome of Budd-Chiari syndrome. Br J Radiol 2021;:20210284. [PMID: 34232733 DOI: 10.1259/bjr.20210284] [Reference Citation Analysis]
7 Tripathi D, Sunderraj L, Vemala V, Mehrzad H, Zia Z, Mangat K, West R, Chen F, Elias E, Olliff SP. Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome. Liver Int. 2017;37:111-120. [PMID: 27254473 DOI: 10.1111/liv.13180] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
8 Bansal V, Gupta P, Sinha S, Dhaka N, Kalra N, Vijayvergiya R, Dutta U, Kochhar R. Budd-Chiari syndrome: imaging review. Br J Radiol 2018;91:20180441. [PMID: 30004805 DOI: 10.1259/bjr.20180441] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]